Psoriasis comorbidities

Authors: Spyridon Gkalpakiotis
Authors‘ workplace: Dermatovenerologická klinika 3. LF UK a FNKV, Praha
Published in: Čas. Lék. čes. 2017; 156: 119-122
Category: Review Article


Psoriasis is a chronic inflammatory skin disease affecting 2–4 % of Central European population. Nowadays, we know that psoriasis is not limited to the skin but is connected with several comorbidities like, psoriatic arthritis (around 25 %), Crohn's disease, ulcerative colitis, Bechterev, non-alcoholic liver steatosis, psychiatric disorders and mainly diseases of the so called metabolic syndrome, like diabetes mellitus type 2, arterial hypertension or dyslipidemia. In the last years, new information is arising which connect psoriasis with sleep apnoe and chronic obstructive pulmonary disease.

psoriasis, comorbidities, metabolic syndrom


1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496–509.

2. Gkalpakiotis S, Arenberger P, Adenubiová E. Psychosociální aspekty života pacientů s psoriázou v České republice. Čes-slov Derm 2013; 4: 189–196.

3. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology 2007; 215: 17–27.

4. Christophers E. Comorbidities in psoriasis. J Eur Acad Dermatol Venerol 2006; 20: 52–55.

5. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venerol 2009; 23: 561–565.

6. Karaca S, Fidan F, Erkan F et al. Might psoriasis be a risk factor for obstructive sleep apnea syndrome? Sleep Breath 2013; 17(1): 275–280.

7. Cetkovská P, Kojanová M. Česká doporučení k biologické léčbě závažné chronické ložiskové psoriázy. Čes-slov Derm 2012; 87(1): 1–30.

8. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007; 370: 272–284.

9. Van de Kerkhof PC. Novel biologic therapies in development targeting IL-12/IL-23. J Eur Acad Dermatol 2010; 24(Suppl. 6): 5–9.

10. Mrowietz U, Leonardi CL, Girolomoni G et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol 2015; 73(1): 27–36.

11. Pina T, Corrales A, Lopez-Mejias R et al. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study. J Dermatol 2016; 43: 1267–1272.

12. Pavelka K et al. Revmatologie. Maxdorf, Praha, 2012.

13. Štork J et al. Dermatovenerologie. Galén, Praha, 2008.

14. Ma C, Harskamp CT, Armstrong EJ, Armstrong AW. The association between psoriasis and dyslipidaemia: a systematic review. Br J Dermatol 2013; 168: 486–495.

15. Armesto S, Santos-Juanes J, Galache-Osuna C et al. Psoriasis and type 2 diabetes risk among psoriatic patients in a Spanish population. Australas J Dermatol 2012; 53(2): 128–130.

16. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008; 159(6): 1331–1337.

17. Natali A, Toschi E, Baldeweg S et al. Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. Diabetes 2006; 55: 1133–1140.

18. Dehghan A, van Hoek M, Sjibrands EJ et al. Risk of type 2 diabetes attributable to C-reactive protein and other risk factors. Diabetes Care 2007; 30: 2695–2699.

19. Armesto S, Coto-Segura P, Osuna CG et al. Psoriasis and hypertension: a case-control study. J Eur Acad Dermatol Venereol 2012; 26(6): 785–788.

20. Qureshi AA, Choi HK, Setty AR et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009; 145: 379–382.

21. Maradit-Kremers H, Dierkhising RA, Crowson CS et al. Risk and predictors of cardiovascular disease in psoriasis: a population-based study. Int J Dermatol 2013; 52(1): 32–40.

22. Kimball AB, Guerin A, Latremouille-Viau D et al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med 2010; 123(4): 350–357.

23. Prodanovich S, Kirsner RS, Kravetz JD et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145(6): 700–703.

24. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002; 4(5): R5.

25. Cheng X, Yu X, Ding YJ et al. The TH17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008; 127: 89–97.

26. Roberts KK, Cochet AE, Lamb PB et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther 2015; 41: 293– 300.

27. Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol 2016; 30(2): 282–287.

28. Rosenberg P, Urwitz H, Johannesson A et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46: 1111–1118.

29. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Chron’s disease. J Eur Acad Dermatol Venereol 2009; 23: 561–565.

30. Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367(16): 1519–1528. See comment in PubMed Commons below.

31. Griffiths CE, Richards HL. Psychological influences in psoriasis. Clin Exp Dermatol 2001; 26: 338–342.

32. Esposito M, Saraceno R, Giunta A et al. An Italian study on psoriasis and depression. Dermatology 2006; 212(2): 123–127.

33. Dreiher J, Weitzman D, Shapiro J et al. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol 2008; 159(4): 956–960.

34. Shalom G, Dreiher J, Cohen A. Psoriasis and obstructive sleep apnea. Int J Dermatol 2016; 55: e579–e584.

35. Wohlrab J, Fiedler G, Gerdes S et al. Recommendations for detection of individual risk for comorbidities in patients with psoriasis. Arch Dermatol Res 2013; 305(2): 91–98.

36. Pina T, Corrales A, Lopez-Mejias R et al. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study. J Dermatol 2016; 43(11): 1267–1272.

37. Pina T, Armesto S, Lopez-Mejias R et al. Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol 2015; 29(7): 1325–1330.

Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management fenix.admin.empty
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account